Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpelisib + olaparib
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Alpelisib (BYL719) and olaparib are two small molecule drugs being studied in combination for the treatment of various cancers, particularly platinum-resistant or refractory high-grade serous ovarian cancer without germline BRCA mutations. Alpelisib is a selective inhibitor of phosphatidylinositol 3-kinase alpha (PI3Kα), which plays a key role in the PI3K/AKT signaling pathway involved in cell growth and survival. Olaparib is a poly(ADP-ribose) polymerase (PARP) inhibitor that disrupts DNA repair processes, leading to tumor cell death, especially in cells with defective homologous recombination repair mechanisms. The combination aims to exploit potential synergistic effects by targeting both DNA repair and cell survival pathways[1][2][4][8].
- Brand names
- Lynparza
- Other names
- alpelisib + olaparib
02
Targets
PIK3CA (Phosphoinositide 3-kinase alpha)PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on alpelisib + olaparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpelisib + olaparib.